Autolus Therapeutics (AUTL) investor relations material

CAR T technology platform and product performance

• Developed a CAR T-cell therapy mimicking physiological T-cell engagement, enabling rapid cell recycling and minimizing overactivation.

• Achieved differentiated safety and efficacy profile, with approval based on the FELIX study for acute leukemia.

• Real-world data from the ROCCA consortium shows product performance aligns with pivotal trial results, with improved safety and efficacy.

• High complete remission rates (>90%) and low rates of severe cytokine release syndrome and neurological toxicity observed.

• Product is being used in older and more difficult-to-treat patients, indicating strong physician confidence.

Commercial progress and market expansion

• Generated $74 million in first-year revenue post-launch, with guidance of $120–$135 million in 2026.

• Steady increase in prescribing physicians and onboarding of treatment centers, targeting 80 centers by year-end.

• U.K. launch benefits from centralized healthcare decisions, accelerating adoption compared to the U.S.

• European expansion is contingent on favorable economic conditions, with ongoing discussions in multiple countries.

Indication and patient population expansion

• Product label allows use in relapsed or refractory patients from second line onward, with interest in frontline consolidation studies.

• Three frontline studies underway, with earliest data expected by end of 2027; potential for guideline inclusion and reimbursement.

• Pediatric CATULUS trial could expand eligible population to all ages, with minimal additional manufacturing investment required.

• Pediatric market estimated at 500+ patients in the U.S., with strong clinical activity and safety profile.